Exercise of Options and Total Voting Rights
Instem plc
("Instem", the "Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, confirms that it has issued 50,000 new ordinary shares of 10p each in the capital of Instem plc (the "New Ordinary Shares"), pursuant to an exercise of share options by a former employee of the Company.
Application has been made to The London Stock Exchange for admission of the New Ordinary Shares to trading on AIM and dealings are expected to commence on 17 September 2021.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,189,856 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 22,189,856 .
Shareholders may use the figure of 22,189,856 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
|
Instem plc |
|
|
Phil Reason, Chief Executive Officer |
+44 (0) 1785 825 600 |
|
Singer Capital Market - NOMAD and Broker |
|
|
Peter Steel, Alex Bond, Daniel Dearden-Williams (Corporate Finance) |
+44 (0) 20 7496 3000 |
|
Walbrook Financial PR |
|
|
Tom Cooper Nick Rome |
+44 (0) 20 7933 8000 |
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 hours ago ASOS
- 10 hours ago MJ Gleeson
- 10 hours ago Rolls-Royce Holdings
- 11 hours ago Crest Nicholson Holdings
- 11 hours ago Naked Wines